Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

ContraFect Q2 EPS $(0.46) Down From $(0.14) YoY

ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.46) per share. This is a 228.57 percent decrease over losses of $(0.14) per share from the same period last year.
byBenzinga Newsdesk
August 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

ContraFect (NASDAQ:CFRX) reported quarterly losses of $(0.46) per share. This is a 228.57 percent decrease over losses of $(0.14) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)

By Benzinga Newsdesk
February 23, 4:27 AM
Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV

GSK